Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol

Background There is an extreme paucity of pharmacokinetic data for anticancer agents in infants. Therefore, we aimed at characterizing the pharmacokinetics for daunorubicin in infants and examined their relationship to age, body weight, and body surface area. Procedure Leukemia patients treated acco...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2010-03, Vol.54 (3), p.355-360
Main Authors: Hempel, Georg, Relling, Mary V., de Rossi, Giulio, Stary, Jan, De Lorenzo, Paola, Valsecchi, Maria Grazia, Barisone, Elena, Boos, Joachim, Pieters, Rob
Format: Article
Language:English
Subjects:
Adolescent
Age
Age Factors
Antibiotics, Antineoplastic - administration & dosage
Antibiotics, Antineoplastic - adverse effects
Antibiotics, Antineoplastic - blood
Antibiotics, Antineoplastic - pharmacokinetics
Antitumor agents
Blood
Body weight
Cancer
Child
Child, Preschool
Children
Computer programs
Data processing
Daunorubicin
Daunorubicin - administration & dosage
Daunorubicin - adverse effects
Daunorubicin - analogs & derivatives
Daunorubicin - blood
Daunorubicin - pharmacokinetics
Female
Humans
Infant
Infant, Newborn
Infants
Infection
Leukemia
Male
Pharmacokinetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma - blood
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
software
Surface area
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background There is an extreme paucity of pharmacokinetic data for anticancer agents in infants. Therefore, we aimed at characterizing the pharmacokinetics for daunorubicin in infants and examined their relationship to age, body weight, and body surface area. Procedure Leukemia patients treated according to the Interfant 99 protocol received 30 mg/m2 daunorubicin, with dose reduction to 3/4 for patients 6–12 months old and 2/3 for patients
ISSN:1545-5009
1545-5017
1545-5017
DOI:10.1002/pbc.22266